Tiemann Investment Advisors LLC Sells 80 Shares of Zoetis Inc. (NYSE:ZTS)

Tiemann Investment Advisors LLC lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,520 shares of the company’s stock after selling 80 shares during the quarter. Tiemann Investment Advisors LLC’s holdings in Zoetis were worth $248,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Daiwa Securities Group Inc. grew its stake in Zoetis by 4.7% during the fourth quarter. Daiwa Securities Group Inc. now owns 75,874 shares of the company’s stock valued at $12,362,000 after acquiring an additional 3,421 shares in the last quarter. Moran Wealth Management LLC increased its holdings in shares of Zoetis by 2.1% in the fourth quarter. Moran Wealth Management LLC now owns 66,596 shares of the company’s stock worth $10,850,000 after purchasing an additional 1,366 shares during the period. Isthmus Partners LLC boosted its stake in Zoetis by 0.3% during the fourth quarter. Isthmus Partners LLC now owns 68,821 shares of the company’s stock valued at $11,213,000 after buying an additional 173 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Zoetis by 5.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 217,094 shares of the company’s stock worth $35,371,000 after acquiring an additional 12,174 shares during the last quarter. Finally, Pettee Investors Inc. raised its holdings in shares of Zoetis by 6.4% in the 4th quarter. Pettee Investors Inc. now owns 11,220 shares of the company’s stock valued at $1,828,000 after acquiring an additional 670 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

ZTS stock opened at $170.34 on Monday. The stock has a market capitalization of $76.28 billion, a price-to-earnings ratio of 31.14, a PEG ratio of 2.78 and a beta of 0.94. The firm’s 50-day moving average price is $166.72 and its two-hundred day moving average price is $176.74. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. As a group, equities analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be given a $0.50 dividend. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis’s dividend payout ratio is 36.56%.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ZTS. Stifel Nicolaus cut their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday. Piper Sandler increased their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Thursday, February 27th. Barclays upped their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $215.90.

Insider Activity at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by corporate insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.